Project Name：Dabigatran etexilate
Registration Classification：3.1
Formulations and specifications ：150mg capsules
Indications：Dabigatran etexilate is a novel synthetic direct thrombin inhibitor , a prodrug of dabigatran , the case of non-peptidic inhibitors of thrombin . There are risks applicable to patients with non- valvular atrial fibrillation to reduce stroke and systemic embolism . Stroke, atrial fibrillation (AF) to prevent initiation .
Original Research Company：German company Boehringer Ingelheim research and development, in 2008, Germany and the United Kingdom.
Progress ：Pharmaceutical Research in progress
Category ： Antiplatelet drugs
